Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
protein degradation
Biotech
Kymera pivots to immunology, seeks partners for cancer assets
Kymera is pivoting to immunology, with plans to only develop cancer programs beyond phase 1 through partnerships.
Gabrielle Masson
Nov 1, 2024 11:46am
Biogen buys in to molecular glues with deal worth up to $1.45B
Oct 30, 2024 10:50am
Novartis inks $150M deal for autoimmune molecular glue
Oct 28, 2024 7:00am
Booster takes off with protein degraders for neurodegeneration
Oct 10, 2024 9:25am
Astellas’ new lab zooms in on targeted protein degradation
Sep 5, 2024 12:01pm
Erasca lays off 18%, swaps out KRAS program for fresh options
May 17, 2024 5:30am
